| 000 | 03175 a2200865 4500 | ||
|---|---|---|---|
| 005 | 20250514075346.0 | ||
| 264 | 0 | _c20031110 | |
| 008 | 200311s 0 0 eng d | ||
| 022 | _a0306-4522 | ||
| 024 | 7 |
_a10.1016/s0306-4522(03)00399-3 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aWidenfalk, J | |
| 245 | 0 | 0 |
_aVascular endothelial growth factor improves functional outcome and decreases secondary degeneration in experimental spinal cord contusion injury. _h[electronic resource] |
| 260 |
_bNeuroscience _c2003 |
||
| 300 |
_a951-60 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. | ||
| 650 | 0 | 4 | _aAnalysis of Variance |
| 650 | 0 | 4 |
_aAngiogenesis Inducing Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aAngiogenesis Inhibitors _xadministration & dosage |
| 650 | 0 | 4 | _aAngiostatins |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 | _aAnimals, Newborn |
| 650 | 0 | 4 |
_aAntigens _xmetabolism |
| 650 | 0 | 4 | _aAstrocytes |
| 650 | 0 | 4 |
_aBehavior, Animal _xdrug effects |
| 650 | 0 | 4 |
_aBlood Vessels _xmetabolism |
| 650 | 0 | 4 |
_aBromodeoxyuridine _xpharmacokinetics |
| 650 | 0 | 4 | _aCell Count |
| 650 | 0 | 4 | _aCell Death |
| 650 | 0 | 4 |
_aCell Division _xdrug effects |
| 650 | 0 | 4 |
_aCerebral Cortex _xmetabolism |
| 650 | 0 | 4 | _aDisease Models, Animal |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 |
_aEndothelial Growth Factors _xgenetics |
| 650 | 0 | 4 |
_aExtracellular Matrix Proteins _xmetabolism |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aGene Expression Regulation |
| 650 | 0 | 4 |
_aGlial Fibrillary Acidic Protein _xmetabolism |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aImmunohistochemistry |
| 650 | 0 | 4 | _aIn Situ Hybridization |
| 650 | 0 | 4 | _aIn Situ Nick-End Labeling |
| 650 | 0 | 4 |
_aIndoles _xmetabolism |
| 650 | 0 | 4 |
_aIntercellular Signaling Peptides and Proteins _xgenetics |
| 650 | 0 | 4 |
_aLymphokines _xgenetics |
| 650 | 0 | 4 |
_aNerve Degeneration _xdrug therapy |
| 650 | 0 | 4 |
_aNeurofilament Proteins _xmetabolism |
| 650 | 0 | 4 |
_aNeuropilin-1 _xgenetics |
| 650 | 0 | 4 |
_aNeuropilin-2 _xgenetics |
| 650 | 0 | 4 |
_aPeptide Fragments _xadministration & dosage |
| 650 | 0 | 4 |
_aPlasminogen _xadministration & dosage |
| 650 | 0 | 4 |
_aRNA, Messenger _xmetabolism |
| 650 | 0 | 4 | _aRandom Allocation |
| 650 | 0 | 4 | _aRats |
| 650 | 0 | 4 | _aRats, Sprague-Dawley |
| 650 | 0 | 4 |
_aReceptors, Vascular Endothelial Growth Factor _xmetabolism |
| 650 | 0 | 4 |
_aRecovery of Function _xphysiology |
| 650 | 0 | 4 |
_aSpinal Cord _xcytology |
| 650 | 0 | 4 |
_aSpinal Cord Injuries _xdrug therapy |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 | _aVascular Endothelial Growth Factor A |
| 650 | 0 | 4 | _aVascular Endothelial Growth Factor Receptor-1 |
| 650 | 0 | 4 | _aVascular Endothelial Growth Factors |
| 650 | 0 | 4 | _aWound Healing |
| 650 | 0 | 4 |
_avon Willebrand Factor _ximmunology |
| 700 | 1 | _aLipson, A | |
| 700 | 1 | _aJubran, M | |
| 700 | 1 | _aHofstetter, C | |
| 700 | 1 | _aEbendal, T | |
| 700 | 1 | _aCao, Y | |
| 700 | 1 | _aOlson, L | |
| 773 | 0 |
_tNeuroscience _gvol. 120 _gno. 4 _gp. 951-60 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/s0306-4522(03)00399-3 _zAvailable from publisher's website |
| 999 |
_c12699091 _d12699091 |
||